Ganciclovir

Generic Name: Ganciclovir

Brand Names: Cytovene, Zirgan

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₅O_₄

CAS Number: 82410-32-0

Unique Ingredient Identifier: P9G3CKZ4P5

Background: An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Indication: For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.

Associated Conditions: CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis

Clinical Trials

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Phase 2

Not yet recruiting

Conditions: SLE (Systemic Lupus)
CMV

Interventions: Drug: Interleukin-2 (IL-2)
Drug: Ganciclovir (GCV)

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 100

Registration Number: NCT06971913

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Bejing, China

Study Evaluating the Efficacy and Safety of Artesunate

Phase 2

Not yet recruiting

Conditions: CMV Infection

Interventions: Drug: Artesunate
Drug: Ganciclovir (GCV)

First Posted Date: 2025-02-28

Last Posted Date: 2025-04-23

Lead Sponsor: Amivas Inc.

Target Recruit Count: 90

Registration Number: NCT06853184

Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis

Not Applicable

Completed

Conditions: Herpetic Keratitis

Interventions: Drug: Ganciclovir (GCV)
Drug: Acyclovir 400 MG

First Posted Date: 2025-01-03

Last Posted Date: 2025-01-03

Lead Sponsor: Al-Azhar University

Target Recruit Count: 20

Registration Number: NCT06757907

Locations: 🇪🇬
Al-Azhar university, Damietta, Egypt

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

Not Applicable

Recruiting

Conditions: Rhinitis, Allergic

Interventions: Drug: Ganciclovir Oral Capsule
Drug: Ganciclovir Simulant Oral Capsule
Drug: Mometasone Nasal

First Posted Date: 2024-05-31

Last Posted Date: 2024-06-24

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 50

Registration Number: NCT06436534

Locations: 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China

Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

Phase 3

Not yet recruiting

Conditions: CMV Infection

Interventions: Drug: Letermovir 480 MG
Drug: Ganciclovir

First Posted Date: 2024-04-02

Last Posted Date: 2024-04-02

Lead Sponsor: Hospital do Rim e Hipertensão

Target Recruit Count: 100

Registration Number: NCT06341686

Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid

Phase 1

Completed

Conditions: Sarcoma
Melanoma
Squamous Cell Carcinoma of Head and Neck
Breast Neoplasms
Uterine Cervical Neoplasms
Vulvar Neoplasms
Penile Neoplasms
Anus Neoplasms

Interventions: Biological: Stimotimagene copolymerplasmid
Drug: Ganciclovir

First Posted Date: 2022-10-13

Last Posted Date: 2024-07-01

Lead Sponsor: Gene Surgery LLC

Target Recruit Count: 21

Registration Number: NCT05578820

Locations: 🇷🇺
FSBI National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Health of Russia, Moscow, Russian Federation
🇷🇺
FSBI N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia, Moscow, Russian Federation
🇷🇺
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russian Federation

and more 1 locations

Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

Phase 3

Active, not recruiting

Conditions: Acute Respiratory Failure

Interventions: Drug: IV Ganciclovir

First Posted Date: 2021-01-12

Last Posted Date: 2025-01-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 500

Registration Number: NCT04706507

Locations: 🇺🇸
University of Colorado Denver, Denver, Colorado, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

and more 17 locations